Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

NZ stocks ride wave of 2026 optimism
Markets

NZ stocks ride wave of 2026 optimism

NZ's sharemarket edged toward record territory on the back of 2026 hopes.

Mammoth application for Santana gold mine
Primary Sector

Mammoth application for Santana gold mine

A 9,400-page submission targets what is said to be NZ's largest gold find in 40 years.

Westpac NZ calls on Google and Meta to do more
Finance

Westpac NZ calls on Google and Meta to do more

CEO says Google, Meta's effort are "piecemeal'"

Baker's dozen: Westpac NZ hikes FY profit by 13%
Finance

Baker's dozen: Westpac NZ hikes FY profit by 13%

Lift for bank's NZ arm comes as Aussie parent sees its bottom line slip.